Previous Close | 44.14 |
1-Year Change | 102.38% |
6-Months Change | 49.98% |
3-Months Change | -5.3% |
Moving Avg (50d) | 44.542 |
Moving Avg (200d) | 36.673 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.47B |
Beta (3-Years) | 1.32 |
Revenue Growth (ttm) | 141.99% |
Net Profit Margin (ttm) | -913.95% |
Return On Assets (ttm) | -21.8% |
EPS (ttm) | -3.95 |
PE Ratio (ttm) | -11.17 |
Dividend Yield | % |
Asset Description: | Agios Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-30 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
45.023 | 46.347 | 47.23 | 48.554 | 50.761 | 52.968 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |